Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Regen BioPharma (RGBPP) over the last 11 years, with Q1 2025 value amounting to $17733.0.

  • Regen BioPharma's Other Non-Current Assets changed 0.0% to $17733.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $17733.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $17733.0 for FY2024, which is 9203.3% down from last year.
  • According to the latest figures from Q1 2025, Regen BioPharma's Other Non-Current Assets is $17733.0, which was down 0.0% from $17733.0 recorded in Q4 2024.
  • In the past 5 years, Regen BioPharma's Other Non-Current Assets ranged from a high of $1.1 million in Q2 2021 and a low of $17733.0 during Q4 2023
  • Over the past 5 years, Regen BioPharma's median Other Non-Current Assets value was $94084.0 (recorded in 2021), while the average stood at $173113.6.
  • As far as peak fluctuations go, Regen BioPharma's Other Non-Current Assets surged by 518078.02% in 2021, and later plummeted by 9203.3% in 2023.
  • Quarter analysis of 5 years shows Regen BioPharma's Other Non-Current Assets stood at $94084.0 in 2021, then surged by 136.58% to $222580.0 in 2022, then plummeted by 92.03% to $17733.0 in 2023, then changed by 0.0% to $17733.0 in 2024, then changed by 0.0% to $17733.0 in 2025.
  • Its Other Non-Current Assets was $17733.0 in Q1 2025, compared to $17733.0 in Q4 2024 and $17733.0 in Q3 2024.